UBS Starts Integra LifeSciences (IART) at Neutral

UBS analyst Patrick Wood initiates coverage on Integra LifeSciences (NASDAQ: IART) with a Neutral rating and a price target of $19.00.

The analyst comments "We initiate coverage of IART with a Neutral rating and a $19 price target. Despite recent regulatory and operational difficulties and a historically high leverage profile, IART's fundamental building blocks are relatively sound: IART is a category leader across end- markets that are themselves structural MSD growers, so the Street's expectations on organic numbers (+2-3% from 3Q26 onward) look feasible, in our eyes, and likely don't require further share gains or above-market execution. Additionally, steady R&D investment (approx. an average of 5.3% of sales, over the last five-years) should help secure growth, and with peak ship-hold disruption behind it, IART's compliance foundation is materially firmer than it was a year ago, which removes a key source of downside risk. On the balance sheet, we think several of the heaviest cash outflows (e.g. the strong inventory build) are entering a period of normalization, and a debt stack that skews fixed (via hedges) makes the forward FCF and deleveraging path more predictable. Overall, our read is that IART has a difficult pathway, with a debt load that caps upside, but one we think is manageable."

For an analyst ratings summary and ratings history on Integra LifeSciences click here. For more ratings news on Integra LifeSciences click here.

Shares of Integra LifeSciences closed at $19.53 yesterday.

You May Also Be Interested In

• BNP Paribas Exane Upgrades Hindustan Unilever Ltd (HUVR:IN) to Outperform
• UBS Starts Edwards Lifesciences (EW) at Buy
• Guggenheim Reiterates Buy Rating on CommVault Systems (CVLT)